EClinCloud Expands Globally, Supporting Over 1,100 Clinical Trials Across Multiple Countries
EClinCloud (Ningbo) Technology Co., Ltd. has surpassed a milestone of supporting over 1,100 clinical trials across more than ten countries and regions using its unified AI-driven platform. The company serves over 300 pharmaceutical, biotech, and CRO organizations with 20,000+ users globally. Its integrated system combines EDC, RTSM, eCOA, CTMS, eTMF, and other clinical tools on a single data model to streamline operations. The platform leverages AI as its core feature rather than an add-on, enabling faster study builds by 60% through protocol parsing agents. It also uses medical OCR with over 95% accuracy for form capture across more than 1,000 types and provides real-time risk modeling for project managers. In 2026, EClinCloud launched its embedded AI agent and next-generation independent review committee (IRC) platform. The company is certified under ISO/IEC 42001:2023 as well as other global standards like GDPR and HIPAA. With a customer base spanning pharmaceuticals, biotechs, CROs, and research institutions, EClinCloud aims to provide an alternative to fragmented eClinical systems in multi-regional trials.
